Seminars in Oncology
Volume 33, Issue 5 , Pages 534-543, October 2006

The Pathology of Renal Epithelial Neoplasms

  • Victor E. Reuter

      Affiliations

    • Corresponding Author InformationAddress correspondence to Victor E. Reuter, MD, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA.

Departments of Pathology, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY.

Renal epithelial neoplasms are morphologically diverse and are characterized by distinct genetic abnormalities. In addition, our understanding of these morphologic differences has allowed us to develop a classification scheme that is more in keeping with their clinical behavior. Clear cell carcinoma is the most common type of renal cell carcinoma (RCC) and accounts for the majority of cases that develop metastatic disease. Papillary carcinoma does not constitute a single morphologic, clinical, or genetic entity with some variants being highly aggressive while others are quite indolent. Chromophobe RCC constitutes less than 10% of primary cases and appears to have a more indolent behavior than clear cell or papillary carcinoma. Oncocytomas are benign, but some cases may be difficult to distinguish from eosinophilic variants of chromophobe RCC. RCC, type unclassified, constitutes up to 7% of cases and represents a histologically and clinically heterogeneous category of tumors that does not fit neatly into any of the other well-defined categories. We have entered the era in which pathologists apply their expertise in microscopy and in evaluating antigenic expression in complex cellular systems to aid in the development and characterization of targeted therapy.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(06)00275-2

doi:10.1053/j.seminoncol.2006.06.009

Seminars in Oncology
Volume 33, Issue 5 , Pages 534-543, October 2006